Abstract:In the last decade, tremendous advances have revolutionized the biological landscape of acute myeloid leukemia (AML). The application of sophisticated molecular biology tools has unveiled a plethora of (epi)genomic and transcriptomic alterations, some of which have been recently recognized in pre-leukemic conditions (e.g. clonal hematopoiesis of indeterminate potential -CHIP 1 ) with implications on AML ontogenesis and prognosis, paving the way for targeted approaches. The most recent diagnostic and prognostic schemes have included these latest advances 2 , further improving the clinical management of AML patients.The present Research Topic has provided a glimpse on some of these aspects, including: 1) new insights on AML biology, with the identification of novel transcriptomic signatures affecting prognosis, mechanistic description of pathogenic mutations (i.e. RAS) and oncogenic fusions (SET-CAN/NUP214) and the recent discoveries on leukemia stem cells (LSCs) at single-cell resolution; 2) new therapeutic perspectives in either induction (lowerdose chemotherapy + venetoclax or alternative chemotherapies for mixed phenotype acute leukemia -MPAL) or relapsed/refractory (R/R) AML (venetoclax + hypomethylating agents -HMA, targeted agent Selinexor, CAR-T cells). As a result, a balanced selection of articles spanning from AML biology and novel prognostic indicators to innovative therapeutic strategies has been selected for the readers.Regarding AML biology, Villar S. and colleagues analyzed the transcriptome of 224 AML patients > 65 years-old at diagnosis treated in the Spanish PETHEMA-FLUGAZA clinical trial in order to identify new prognostic biomarkers in this population. They identified a specific transcriptomic signature for high-risk patients, revealing that low expression of B7H3 gene with high expression of BANP gene identifies a subset with a more favorable prognosis surviving more than 12 months. This result was further validated in the BEAT AML cohort.Zhang J. et al focused on autophagy, since beside being known as a natural cellular response to a wide spectrum of cellular processes, it is debated whether it might have a pathogenic role in leukemias and particularly in AML. The authors found >100 differentially expressed genes (DEGs) related to autophagy between AML and healthy controls. Next, they selected 12 of these genes and developed a prognostic model predictive for survival of AML patients in both TCGA data and independent AML cohorts from GEO databases.Wan P. et al in a first-time approach based on the differential expression of lysosomerelated genes in AML identified two different subtypes: cluster1 showed longer overall survival (OS) and stronger immune infiltration compared to cluster2. The pivotal differential genes between the two clusters are SYK, whose pro-carcinogenic mechanism relies in the promotion of AML cell survival and drug resistance 3 , and TLR4 which is thought to modulate lysosomal function and is in turn degraded by lysosome themselves 4 . Finally, a prognostic model consisting of six genes identified patients in a low-risk group who survived significantly longer than those in the high-risk group and had higher immune infiltration and stronger response to immunotherapy.Further, Song J. and colleagues unravel the role of SET-CAN/NUP214 fusion in leukemia. This aberration mainly occurs in T-cell acute lymphoblastic leukemia (T-ALL) patients, but it has also been reported in other leukemias including AML, MPAL and B-ALL. Leukemias bearing this fusion often share common immunophenotypic markers such as: CD7, cCD3, CD34, CD33 and CD13. This supports a model where the transformation of SET-CAN/NUP214+ leukemia may occur in the early stage of myeloid or lymphocyte differentiation, and it may be related to the inhibition of differentiation of primitive progenitor cells by the fusion gene. Patients with SET-CAN/NUP214 fusion usually exhibit resistance to chemotherapy, including glucocorticoids in the early stages of induction therapy, however the overall CR rate is not affected.In another original paper, Liang T. et al focus on the pathogenic role of RAS mutations in AML, and their impact on cell metabolism. In fact, RAS gene mutations are prevalent in AML, and the RAS signaling pathway is closely related to many metabolic pathways. By using a Ba/F3 cell line model transduced with NRAS Q61K and KRAS G12V mutations, the authors conducted a DEG analysis between mutant and wild-type cell lines. They found 1899 DEGs, of which 1089 were related to metabolic pathways, particularly the DGKzeta and PLA2G4A genes in the glycerophospholipid metabolism pathway were significantly upregulated. These findings may contribute to new precision therapy strategies and the development of new therapeutic drugs for AML.In a comprehensive review, Zhou J. et al provide a detailed summary of single-cell sequencing strategies in AML. These techniques ha -Abstract Truncated-

Unbiased Subtyping of AML: Unraveling Genomic and Transcriptomic Features for Precision Medicine and Targeted Therapies Using Beat-AML and TCGA Data

Abstract 6206: Molecular stratification of AML: Integrative genomic and immune profiling points to high risk subgroup and targetable molecular drivers

A Risk Score Combined Clinical and Molecular Profiles Identifies a High-Risk Subgroup Within AML1-ETO-Positive Acute Myeloid Leukemia

MicroRNA Expression Profiles in Acute Myeloid Leukemia with Common Translocations.

Identification of Potential Novel Prognosis-Related Genes Through Transcriptome Sequencing, Bioinformatics Analysis, and Clinical Validation in Acute Myeloid Leukemia

Dissecting Subtype-Specific Tumor-Time Interactions and Underlying Hidden Drivers in Pediatric Acute Myeloid Leukemia Via Single-Cell Multi-Omics

Molecular subtyping of acute myeloid leukemia through ferroptosis signatures predicts prognosis and deciphers the immune microenvironment

Gene Expression Machine Learning Models Classify Pediatric AML Subtypes with High Performance

Integrative Multi-Omic Analysis for Prognosis Stratification in Acute Myeloid Leukemia

Mapping AML heterogeneity - multi-cohort transcriptomic analysis identifies novel clusters and divergent ex-vivo drug responses

Seventeen-Gene Signature Identifies AML Cells in Single Cell RNA Sequencing Data and Resolves Treatment Resistant Subtypes

Molecular Characterization of the Highest Risk Adult Patients With Acute Myeloid Leukemia (AML) Through Multi-Omics Clustering

Molecular precision medicine: Multi-omics-based stratification model for acute myeloid leukemia

Clinico-Genomic Characterization of AML Patients Based on IL2RA (CD25) Expression Uncovers an Association with Stem Cell Signatures and FLT3-ITD Status and Informs Drug Combinations

Impact of Molecular Clonality on Survival in Acute Myeloid Leukemia

Editorial: Novelties in acute myeloid leukemia: from biology to clinical applications

Transcriptome-based molecular subtypes and differentiation hierarchies improve the classification framework of acute myeloid leukemia

Integration of Deep Multi-Omics Profiling Veals New Insights into the Biology of Poor-Risk Acute Myeloid Leukemia

Combined Single-Cell DNA Genotyping and Protein Quantification (DAb-seq) in Acute Myeloid Leukemias Reveals Distinct Immunophenotypic Subsets Among Pathogenic Clones

Decoupling Lineage-Associated Genes in Acute Myeloid Leukemia Reveals Inflammatory and Metabolic Signatures Associated With Outcomes

Paired single-B-cell transcriptomics and receptor sequencing reveal activation states and clonal signatures that characterize B cells in acute myeloid leukemia